دورية أكاديمية
أعرض في EDS

Dietary supplement use and recommendations for discontinuation in an integrative oncology clinic.

التفاصيل البيبلوغرافية
العنوان: Dietary supplement use and recommendations for discontinuation in an integrative oncology clinic.
المؤلفون: D'Andre SD; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Dandre.stacy@mayo.edu., Bauer BA; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Hofmann MB; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Burckhard JL; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Montane HN; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA., Loprinzi CL; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Dec 16; Vol. 31 (1), pp. 40. Date of Electronic Publication: 2022 Dec 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer International, c1993-
مواضيع طبية MeSH: Integrative Oncology* , Neoplasms*/drug therapy, Humans ; Dietary Supplements ; Vitamins/adverse effects ; Iron
مستخلص: Purpose: This project evaluated the dietary supplement (DS) use of patients referred to an integrative oncology program and documented the frequency and reasons for recommending stopping DS. Many patients with cancer are taking dietary supplements and may not disclose such to their care teams. There is potential for harm in several ways: (1) interactions with their medications that may increase side effects, (2) interactions with their treatment that may lead to decreased efficacy, and 3) direct toxicity from the supplement.
Methods: Patient data (N = 100) were collected prospectively from an Integrative Oncology Clinic. The number and type of DS were documented. Using the Natural Medicines Database, we determined whether supplements interacted with the patient's other medications or cancer therapies. We calculated the percentage of patients in which a recommendation for discontinuation (DC) of DS was provided, along with the supporting reasons.
Results: We found that 91% of patients took DS, averaging 5.5 per patient (range 0-20). In 35% of patients, we recommended stopping some of their DS or other therapies, the reasons being: DC antioxidants, vitamin B12/iron while on chemo/RT (unless deficient or part of protocol) 32%; DC due to taking excess amounts (i.e., fat-soluble vitamins, calcium, iron) 13.5%; DC supplements with known toxicity (i.e., laetrile, Miracle mineral solution) 13.5%; DC due to interactions with other medications (i.e., anticoagulants) 13.5%; DC DS with potential to increase cancer growth (i.e., estrogenic potential in those with hormone-sensitive cancers, glutamine) 11%; DC due to potential for increased toxicity with chemotherapy (i.e., increased risk of bleeding, CIPN) 11%; DC probiotics, immune stimulants, and cannabis while on immunotherapy 5.4%.
Conclusions: Patients with cancer referred to an integrative oncology clinic use large numbers of DS with the potential for adverse effects and/or decreasing efficacy of treatments. This study highlights the prevalence of DS usage in cancer patients referred to an integrative oncology clinic and demonstrates the need for counseling about safe supplement use.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: https://ods.od.nih.gov/factsheets/DietarySupplements-Consumer/ . Accessed Dec 2022.
Du M, Luo H, Blumberg JB, Rogers G, Chen F, Ruan M, Shan Z, Biever E, Zhang FF (2020) Dietary supplement use among adult cancer survivors in the United States. J Nutr 150(6):1499–1508. https://doi.org/10.1093/jn/nxaa040. (PMID: 10.1093/jn/nxaa040)
Davis EL, Oh B, Butow PN, Mullan BA, Clarke S (2012) Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist 17(11):1475–1481. https://doi.org/10.1634/theoncologist.2012-0223. (PMID: 10.1634/theoncologist.2012-0223)
Mengxi Du, Luo H (2020) Jeffrey B Blumberg, Gail Rogers, Fan Chen, Mengyuan Ruan, Zhilei Shan, Emily Biever, Fang Fang Zhang, Dietary supplement use among adult cancer survivors in the United States. J Nutr 150(6):1499–1508. https://doi.org/10.1093/jn/nxaa040. (PMID: 10.1093/jn/nxaa040)
Conway RE, Rigler FV, Croker HA, Lally PJ, Beeken RJ, Fisher A (2022) Dietary supplement use by individuals living with and beyond breast, prostate, and colorectal cancer: A cross-sectional survey. Cancer. https://doi.org/10.1002/cncr.34055. (PMID: 10.1002/cncr.34055)
Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26(4):665–673. https://doi.org/10.1200/JCO.2007.13.5905. (PMID: 10.1200/JCO.2007.13.5905)
Buckner CA, Lafrenie RM, Dénommée JA, Caswell JM, Want DA (2018) Complementary and alternative medicine use in patients before and after a cancer diagnosis. Curr Oncol 25(4):e275–e281. https://doi.org/10.3747/co.25.3884. (PMID: 10.3747/co.25.3884)
Abdel-Rahman O (2021) Dietary supplements use among adults with cancer in the United States: a population-based study. Nutr Cancer 73(10):1856–1863. https://doi.org/10.1080/01635581.2020.1820050. (PMID: 10.1080/01635581.2020.1820050)
Johnson SB, Park HS, Gross CP, Yu JB (2018) Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol 4(10):1375–1381. https://doi.org/10.1001/jamaoncol.2018.2487. (PMID: 10.1001/jamaoncol.2018.2487)
www.naturalmedicines.therapeuticsresearch.com . Accessed Dec 2022.
Drozdoff L, Klein E, Kalder M, Brambs C, Kiechle M, Paepke D (2019) Potential interactions of biologically based complementary medicine in gynecological oncology. Integr Cancer Ther 18:1534735419846392. https://doi.org/10.1177/1534735419846392. (PMID: 10.1177/1534735419846392)
Ferrucci LM, McCorkle R, Smith T, Stein KD, Cartmel B (2009) Factors related to the use of dietary supplements by cancer survivors. J Altern Complement Med 15(6):673–680. https://doi.org/10.1089/acm.2008.0387. (PMID: 10.1089/acm.2008.0387)
Buckner CA, Lafrenie RM, Dénommée JA, Caswell JM, Want DA (2018) Complementary and alternative medicine use in patients before and after a cancer diagnosis. Curr Oncol 25(4):e275–e281. https://doi.org/10.3747/co.25.3884.
Raber M, Warner EL, Leroy G, Crane T, Badget T, Basen-Engquist K (2021) Cancer- related nutrition and meal planning content on Pinterest. ASPO abstracts. https://aspo.org/abstracts/abstract-details/?pdb=2952.
Luo Q, Asher GN (2018) Use of dietary supplements at a comprehensive cancer center. J Altern Complement Med 24(9–10):981–987. https://doi.org/10.1089/acm.2018.0183. (PMID: 10.1089/acm.2018.0183)
Pourroy B et al (2017) Development of a rapid risk evaluation tool for herbs/drugs interactions in cancer patients: a multicentric experience in south of France. Eur J Cancer Care 26(6):e12752. (PMID: 10.1111/ecc.12752)
Harvie M (2014) Nutritional supplements and cancer: potential benefits and proven harms. Am Soc Clin Oncol Educ Book e478–86. https://doi.org/10.14694/EdBook_AM.2014.34.e478.
Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633. https://doi.org/10.1200/JCO.2012.44.8738. (PMID: 10.1200/JCO.2012.44.8738)
Vatistas TJ, Samuels JG (2012) The regulation of dietary supplements in the United States: advocating for a reasonable approach, protecting patient safety, and the role of nursing. Policy Polit Nurs Pract 13(2):113–116. https://doi.org/10.1177/1527154412456706. (PMID: 10.1177/1527154412456706)
Levy I, Attias S, Ben-Arye E, Goldstein L, Schiff E (2017) Adverse events associated with interactions with dietary and herbal supplements among inpatients. Br J Clin Pharmacol 83(4):836–845. https://doi.org/10.1111/bcp.13158. (PMID: 10.1111/bcp.13158)
Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, Courneya KS, Dryden T, Hanser S, Kumar N, Labriola D, Wardell DW, Sagar S (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7(3):85–120. https://doi.org/10.2310/7200.2009.0019. (PMID: 10.2310/7200.2009.0019)
https://www.nccn.org/patients/guidelines/content/PDF/survivorship-hl-patient.pdf . Accessed Oct 2022.
https://www.aicr.org/resources/media-library/10-cancer-prevention-recommendations/ . Accessed Dec 2022.
Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Number M, Seely D, Zick SM, Boyce LM, Tripathy D, Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L (2018) Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 36(25):2647–2655. https://doi.org/10.1200/JCO.2018.79.2721. (PMID: 10.1200/JCO.2018.79.2721)
Woo JJ (2007) Adverse event monitoring and multivitamin-multimineral dietary supplements. Am J Clin Nutr 85(1):323S-324S. https://doi.org/10.1093/ajcn/85.1.323S. (PMID: 10.1093/ajcn/85.1.323S)
Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS (2020) Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J Clin Oncol 38(8):804–814. https://doi.org/10.1200/JCO.19.01203. (PMID: 10.1200/JCO.19.01203)
Oh B, Butow P, Mullan B, Clarke S, Tattersall M, Boyer M, Beale P, Vardy J, Pavlakis N, Larke L (2010) Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. J Soc Integr Oncol Spring 8(2):56–64.
Smithson J, Britten N, Paterson C, Lewith G, Evans M (2012) The experience of using complementary therapies after a diagnosis of cancer: a qualitative synthesis. Health (London) 16(1):19–39. https://doi.org/10.1177/1363459310371081. (PMID: 10.1177/1363459310371081)
Delgado-López PD, Corrales-García EM (2018) Influence of internet and social media in the promotion of alternative oncology, cancer quackery, and the predatory publishing phenomenon. Cureus 10(5):e2617. https://doi.org/10.7759/cureus.2617. (PMID: 10.7759/cureus.2617)
Tank M, Franz K, Cereda E, Norman K (2021) Dietary supplement use in ambulatory cancer patients: a survey on prevalence, motivation and attitudes. J Cancer Res Clin Oncol 147(7):1917–1925. https://doi.org/10.1007/s00432-021-03594-7. (PMID: 10.1007/s00432-021-03594-7)
Holmes MM, Bishop FL, Calman L (2017) “I just googled and read everything”: Exploring breast cancer survivors’ use of the internet to find information on complementary medicine. Complement Ther Med 33:78–84. https://doi.org/10.1016/j.ctim.2017.06.007. (PMID: 10.1016/j.ctim.2017.06.007)
Schmidt K, Ernst E (2004) Assessing websites on complementary and alternative medicine for cancer. Ann Oncol 15(5):733–742. https://doi.org/10.1093/annonc/mdh174. (PMID: 10.1093/annonc/mdh174)
Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE (2001) Americans’ views on the use and regulation of dietary supplements. Arch Intern Med 161(6):805–810. https://doi.org/10.1001/archinte.161.6.805. (PMID: 10.1001/archinte.161.6.805)
Sungu-Winkler KT, Hubner J, Menge F et al (2018) The use of complementary and alternative medicine in sarcoma patients. Ann Onc 29(8) ESMO abstract #3276.
Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 10(4):177. https://doi.org/10.3389/fphar.2013.00177. (PMID: 10.3389/fphar.2013.00177)
Shen J, Andersen R, Albert PS et al (2002) Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2(8):1–7. https://doi.org/10.1186/1472-6882-2-8.
Ritvo P, Irvine J, Katz J, Matthew A, Sacamano J, Shaw BF (1999) The patient’s motivation in seeking complementary therapies. Patient Educ Couns 38(2):161–165. https://doi.org/10.1016/s0738-3991(99)00063-4. (PMID: 10.1016/s0738-3991(99)00063-4)
Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A (2005) Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 4(4):274–286. https://doi.org/10.1177/1534735405282361. (PMID: 10.1177/1534735405282361)
Helyer LK, Chin S, Chui BK, Fitzgerald B, Verma S, Rakovitch E, Dranitsaris G, Clemons M (2006) The use of complementary and alternative medicines among patients with locally advanced breast cancer–a descriptive study. BMC Cancer 21(6):39. https://doi.org/10.1186/1471-2407-6-39. (PMID: 10.1186/1471-2407-6-39)
Frenkel M, Cohen L (2014) Effective communication about the use of complementary and integrative medicine in cancer care. J Alternat Complement Med 20(1):12–18. (PMID: 10.1089/acm.2012.0533)
Molassiotis A, Fernández-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16(4):655–663. https://doi.org/10.1093/annonc/mdi110. (PMID: 10.1093/annonc/mdi110)
Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103(3):323–328. https://doi.org/10.1053/jada.2003.50045. (PMID: 10.1053/jada.2003.50045)
Oliver JE, Wood T (2014) Medical conspiracy theories and health behaviors in the United States. JAMA Intern Med 174(5):817–818. https://doi.org/10.1001/jamainternmed.2014.19010.1186/1472-6882-2-8. (PMID: 10.1001/jamainternmed.2014.19010.1186/1472-6882-2-8)
Hirai K, Komura K, Tokoro A, Kuromaru T, Ohshima A, Ito T, Sumiyoshi Y, Hyodo I (2008) Psychological and behavioral mechanisms influencing the use of complementary and alternative medicine (CAM) in cancer patients. Ann Oncol 19(1):49–55. https://doi.org/10.1093/annonc/mdm494. (PMID: 10.1093/annonc/mdm494)
Bellesoeur A, Gataa I, Jouinot A et al (2018) Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration. Ann Onc 29(8) ESMO abstract #5767.
Shi S, Klotz U (2012) Drug interactions with herbal medicines. Clin Pharmacokinet 51:77–104. https://doi.org/10.2165/11597910-000000000-00000. (PMID: 10.2165/11597910-000000000-00000)
Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I (2013) Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 39(7):773–783. https://doi.org/10.1016/j.ctrv.2012.12.008. (PMID: 10.1016/j.ctrv.2012.12.008)
Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C (2017) Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract 13(7):e613–e622. https://doi.org/10.1200/JOP.2017.020859. (PMID: 10.1200/JOP.2017.020859)
Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E, Charalambous H, Dweikat T, Ghrayeb I, Bar-Sela G, Turker I, Hassan A, Hassan E, Saad B, Nimri O, Kebudi R, Silbermann M (2016) Potential risks associated with traditional herbal medicine use in cancer care: A study of Middle Eastern oncology health care professionals. Cancer 122:598–610. https://doi.org/10.1002/cncr.29796. (PMID: 10.1002/cncr.29796)
Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Huebner J (2022) Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. J Cancer Res Clin Oncol 148(5):1123–1135. https://doi.org/10.1007/s00432-021-03675-7. (PMID: 10.1007/s00432-021-03675-7)
Jermini M, Dubois J, Rodondi PY, Zaman K, Buclin T, Csajka C, Orcurto AE, Rothuizen L (2019) Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Sci Rep 9(1):5078. https://doi.org/10.1038/s41598-019-41532-3. (PMID: 10.1038/s41598-019-41532-3)
Alsanad SM, Williamson EM, Howard RL (2014) Cancer patients at risk of herb/food supplement–drug interactions: a systematic review. Phytother Res 28:1749–1755. https://doi.org/10.1002/ptr.5213. (PMID: 10.1002/ptr.5213)
Alsanad SM, Howard RL, Williamson EM (2016) An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement Altern Med 16:393. https://doi.org/10.1186/s12906-016-1372-x. (PMID: 10.1186/s12906-016-1372-x)
Wells JC, Sidhu A, Ding K, et al (2022) Complementary medicine use amongst patients with metastatic cancer enrolled in phase III clinical trials, The Oncologist 27(3):e286–e293.  https://doi.org/10.1093/oncolo/oyac020.
https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database. Accessed Oct 2022.
Raynor DK, Dickinson R, Knapp P et al (2011) Buyer beware? Does the information provided with herbal products available over the counter enable safe use? BMC Med 9:94. https://doi.org/10.1186/1741-7015-9-94. (PMID: 10.1186/1741-7015-9-94)
Daenen LG, Cirkel GA, Houthuijzen JM, Gerrits J, Oosterom I, Roodhart JM, van Tinteren H, Ishihara K, Huitema AD, Verhoeven-Duif NM, Voest EE (2015) Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncol 1(3):350–358. https://doi.org/10.1001/jamaoncol.2015.0388. (PMID: 10.1001/jamaoncol.2015.0388)
Tournas VH (2009) Microbial contamination of select dietary supplements. J Food Saf 29:430–442. https://doi.org/10.1111/j.1745-4565.2009.00167.x. (PMID: 10.1111/j.1745-4565.2009.00167.x)
Genuis SJ, Schwalfenberg G, Siy A-KJ, Rodushkin I (2012) Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One 7(11):e49676. https://doi.org/10.1371/journal.pone.0049676. (PMID: 10.1371/journal.pone.0049676)
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R (2017) Labeling accuracy of cannabidiol extracts sold online. JAMA 318(17):1708–1709. https://doi.org/10.1001/jama.2017.11909. (PMID: 10.1001/jama.2017.11909)
Eisele JW, Reay DT (1980) Deaths related to coffee enemas. JAMA 244(14):1608–1609. https://doi.org/10.1001/jama.1980.03310140066036. (PMID: 10.1001/jama.1980.03310140066036)
https://www.consumerlab.com/recalls/14573/family-indicted-for-selling-dangerous-bleach-miracle-mineral-solution-as-covid-cure/ . Accessed Dec 2022 .
PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Laetrile/Amygdalin (PDQ®): Health Professional Version (2022) In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK65988/.
Jiang Hu, Webster D, Cao J, Shao A (2018) The safety of green tea and green tea extract consumption in adults – results of a systematic review. Regul Toxicol Pharmacol 95:412–433. (PMID: 10.1016/j.yrtph.2018.03.019)
Bhoo-Pathy N, Subramaniam S, Khalil S, Kimman M, Kong Y-C, Ng C-W, Bustamam RS, Yip C-H (2021) Out-of-pocket costs of complementary medicine following cancer and the financial impact in a setting with universal health coverage: findings from a prospective cohort study. JCO Oncol Pract 17(10):e1592–e1602. (PMID: 10.1200/OP.20.01052)
Kong Y-C et al (2022) Out-of-pocket payments for complementary medicine following cancer and the effect on financial outcomes in middle-income countries in Southeast Asia: a prospective cohort study. Lancet Glob Health 10.3:e416–e428. (PMID: 10.1016/S2214-109X(21)00595-7)
فهرسة مساهمة: Keywords: Cancer; Complementary medicine; Dietary supplements; Drug interactions; Integrative oncology
المشرفين على المادة: 0 (Vitamins)
E1UOL152H7 (Iron)
تواريخ الأحداث: Date Created: 20221216 Date Completed: 20221220 Latest Revision: 20221222
رمز التحديث: 20231215
DOI: 10.1007/s00520-022-07504-6
PMID: 36525104
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-7339
DOI:10.1007/s00520-022-07504-6